Cargando…
Advances in DNA sequence specific agents /
This series encompasses design, synthesis, application, and analytical methods (including clinical and in vitro) for the study of these critical interactions. As our understanding of the genome and proteome expands, general developments in the field of DNA sequence specific interaction are likely to...
| Clasificación: | Libro Electrónico |
|---|---|
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Amsterdam, the Netherlands :
Elseview Science B.V.,
�2002.
|
| Edición: | 1st ed. |
| Colección: | Advances in DNA sequence specific agents ;
v. 4. |
| Temas: | |
| Acceso en línea: | Texto completo Texto completo |
MARC
| LEADER | 00000cam a2200000 a 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_ocn162135933 | ||
| 003 | OCoLC | ||
| 005 | 20231117014910.0 | ||
| 006 | m o d | ||
| 007 | cr cn||||||||| | ||
| 008 | 070802s2002 ne a ob 000 0 eng d | ||
| 040 | |a OPELS |b eng |e pn |c OPELS |d OPELS |d BAKER |d OPELS |d OCLCQ |d N$T |d YDXCP |d OCLCQ |d MERUC |d OCLCQ |d OCLCO |d OCLCQ |d OCLCF |d OCLCQ |d UIU |d EBLCP |d MHW |d UKDOC |d OCLCQ |d DEBSZ |d UAB |d OCLCO |d OCLCA |d D6H |d CHVBK |d OCLCQ |d LEAUB |d OCLCO |d OL$ |d OCLCQ |d OCLCA |d OCLCQ |d OCLCA |d S2H |d OCLCO |d OCLCQ |d OCLCO | ||
| 019 | |a 173240862 |a 173413900 |a 476079333 | ||
| 020 | |a 9780080526133 |q (electronic bk.) | ||
| 020 | |a 0080526136 |q (electronic bk.) | ||
| 020 | |z 9780444510969 | ||
| 020 | |z 0444510966 | ||
| 035 | |a (OCoLC)162135933 |z (OCoLC)173240862 |z (OCoLC)173413900 |z (OCoLC)476079333 | ||
| 050 | 4 | |a QP624 |b .A38 2002 | |
| 060 | 4 | |a QU 58.5 |b A244 2002 | |
| 072 | 7 | |a SCI |x 029000 |2 bisacsh | |
| 082 | 0 | 4 | |a 572.8/633 |2 22 |
| 245 | 0 | 0 | |a Advances in DNA sequence specific agents / |c series editor, Graham B. Jones ; volume editor, Brant J. Chapman. |
| 250 | |a 1st ed. | ||
| 260 | |a Amsterdam, the Netherlands : |b Elseview Science B.V., |c �2002. | ||
| 300 | |a 1 online resource (viii, 151 pages) : |b illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Advances in DNA sequence specific agents ; |v v. 4 | |
| 504 | |a Includes bibliographical references. | ||
| 505 | 0 | |a Preferential damage to defined regions of genomic DNA by AT-specific anticancer drugs -- DNA-alkylating events associated with nitrogen mustard based anticancer drugs and the metabolic by product Acrolein -- Molecular basis for recognition and binding of specific DNA sequences by calicheamicin and duocarmycin -- Enediyne antibiotic neocarzinostatin as a radical-based probe of bulged structures in nucleic acids -- Sequence-specific DNA binding by short peptides -- Equilibrium and kinetic quantitative DNase 1 footprinting. | |
| 520 | |a This series encompasses design, synthesis, application, and analytical methods (including clinical and in vitro) for the study of these critical interactions. As our understanding of the genome and proteome expands, general developments in the field of DNA sequence specific interaction are likely to play an increasingly important role. Accordingly, manuscripts have been solicited from experts covering a diverse range of fields, reflecting the cross-disciplinary and dynamic nature of the series. Volume 4 describes work on the modification of DNA by AT specific anticancer drugs, DNA alkylation events which involve metabolite generation, DNA sequence recognition by two selective binders, bulged DNA microenvironments as molecular targets, DNA sequence specific binding by short peptides and the analysis of DNA-protein interactions using DNase I footprinting methodology. Features include: & bull; Expert contributors from the Biomedical world & bull; Emerging areas of drug design and therapeutic applications & bull; Nucleic acid-protein interactions & bull; Color graphics of molecular modeling analyses & bull; New and emerging methodologies. | ||
| 588 | 0 | |a Print version record. | |
| 650 | 0 | |a DNA. | |
| 650 | 0 | |a Nucleotide sequence. | |
| 650 | 2 | |a DNA |0 (DNLM)D004247 | |
| 650 | 2 | |a Sequence Analysis, DNA |0 (DNLM)D017422 | |
| 650 | 6 | |a ADN. |0 (CaQQLa)201-0008510 | |
| 650 | 7 | |a SCIENCE |x Life Sciences |x Genetics & Genomics. |2 bisacsh | |
| 650 | 7 | |a DNA |2 fast |0 (OCoLC)fst00886555 | |
| 650 | 7 | |a Nucleotide sequence |2 fast |0 (OCoLC)fst01041106 | |
| 776 | 0 | 8 | |i Print version: |t Advances in DNA sequence specific agents. |b 1st ed. |d Amsterdam, the Netherlands : Elseview Science B.V., �2002 |z 0444510966 |z 9780444510969 |w (OCoLC)54059256 |
| 830 | 0 | |a Advances in DNA sequence specific agents ; |v v. 4. | |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/book/9780444510969 |z Texto completo |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/bookseries/1067568X/4 |z Texto completo |